Skip to main content

New Products

  • Rx Response reporting system gets name change

    NEW ORLEANS — A coalition of drug and pharmacy organizations formed to address patients' medication needs during disasters is changing the name and Web address of its reporting system to make it easier to remember, the organization said Tuesday.

  • Lifestyles launches new Turbo condoms

    ISELIN, N.J. — The makers of LifeStyles condoms today announced the release of the new Turbo condom. The Turbo condom is lubricated inside and out with LifeStyles' proprietary Excite gel.

  • FDA approves new Teva contraceptive

    JERUSALEM — The Food and Drug Administration has approved a new contraceptive therapy made by Teva Pharmaceutical Industries, Teva said Monday.

    The drug maker announced the approval of Quartette (levonorgestrel, ethinyl estradiol and ethinyl estradiol) tablets. Teva said the drug represented the "next generation" of extended-regimen oral contraceptives and was designed to minimize breakthrough bleeding between scheduled periods.

  • Actavis seeks approval for additional strength of generic testosterone gel

    PARSIPPANY, N.J. — Just a week after the Supreme Court heard the Federal Trade Commission's lawsuit over its deal with AbbVie to sell a generic version of a testosterone-replacement therapy, Actavis is challenging the patent on another strength of the drug.

    Actavis said Monday that it had filed with the Food and Drug Administration for approval of testosterone gel in the 1.62% strength. The drug is a generic version of AbbVie's AndroGel 1.62%. The case that went before the Supreme Court on March 25 concerns the 1% strength of AndroGel.

  • Medicare dashboard advances ACA goals for chronic conditions

    WASHINGTON — A new Medicare Chronic Conditions Dashboard announced today by Marilyn Tavenner, acting administrator of the Centers for Medicare and Medicaid Services (CMS), furthers the Patient Protection and Affordable Care Act’s goals for health promotion and the prevention and management of multiple chronic conditions.

  • FDA approves J&J diabetes drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Johnson & Johnson for treating Type 2 diabetes, the agency said.

    The FDA announced the approval of J&J subsidiary Janssen Pharmaceuticals' Invokana (canagliflozin) tablets, designed for use with diet and exercise to improve blood-sugar control in adults with the disease.

  • Dr. Reddy's launches generic acne drug

    HYDERABAD, India — Dr. Reddy's has launched a drug for treating acne, the company said Friday.

    The Indian generic drug maker announced the launch of Zenatane (isotretinoin) capsules in the 20-mg and 40-mg strengths. The drug is a therapeutically equivalent generic version of Roche's Accutane. The Food and Drug Administration also approved the drug in the 10-mg strength.

    Various versions of the drug had sales of about $309 million during the 12-month period that ended in January, according to IMS Health.

     

  • Reports: Walmart considers customer-to-customer delivery service

    BENTONVILLE, Ark. — As Reuters reported yesterday, Walmart is considering a new delivery system that would have in-store customers deliver packages to online buyers. The delivering customers would receive a discount off their shopping bills.

X
This ad will auto-close in 10 seconds